(IMCD) IMCD - Overview
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: AS (Netherlands) | Market Cap: 5.691m EUR | Total Return: -25.4% in 12m
Specialty Chemicals, Food Ingredients, Pharmaceutical Additives, Lubricants
Total Rating 56
Safety 84
Buy Signal -0.21
Specialty Chemicals
Industry Rotation: -1.2
Industry Rotation: -1.2
Market Cap:
6.62B
Avg Turnover: 21.0M
Avg Turnover: 21.0M
Risk 3d forecast
Volatility30.4%
VaR 5th Pctl4.90%
VaR vs Median-2.09%
Reward TTM
Sharpe Ratio-0.59
Rel. Str. IBD43
Rel. Str. Peer Group51.6
Character TTM
Beta0.156
Beta Downside0.160
Hurst Exponent0.570
Drawdowns 3y
Max DD56.73%
CAGR/Max DD-0.18
CAGR/Mean DD-0.47
Warnings
No concerns identified
Tailwinds
Confidence
Description: IMCD IMCD
IMCD NV is a global distributor of specialty chemicals and ingredients, operating across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region. Headquartered in Rotterdam, the company serves a diverse range of end-markets including pharmaceuticals, personal care, food and nutrition, and industrial coatings.
The business model functions as an intermediary between chemical producers and end-users, providing technical expertise and formulation support rather than just logistics. In the specialty chemical sector, distributors typically benefit from high barriers to entry due to the technical complexity of the products and the fragmented nature of the customer base.
The product portfolio encompasses thousands of additives, resins, surfactants, and active ingredients used in everything from sunscreens and lubricants to food texture agents. Investors looking for deeper insights into these market segments may find ValueRays analytical tools useful for further due diligence.
- M&A execution and successful integration of regional specialty chemical distributors
- Global manufacturing output fluctuations impact demand for industrial and technical additives
- Life sciences portfolio growth provides defensive earnings buffer during economic downturns
- Supply chain volatility and inventory destocking cycles affect gross profit margins
- Regulatory shifts in ingredients safety standards influence product mix and compliance costs
Piotroski VR‑10 (Strict)
8.0
| Net Income: 495.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.55 > 1.0 |
| NWC/Revenue: 7.98% < 20% (prev 23.03%; Δ -15.05% < -1%) |
| CFO/TA 0.13 > 3% & CFO 601.5m > Net Income 495.8m |
| Net Debt (1.46b) to EBITDA (1.10b): 1.33 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (59.1m) vs prev 3.35% < -2% |
| Gross Margin: 18.07% > 18% (prev 0.12%; Δ 1.80k% > 0.5%) |
| Asset Turnover: 200.3% > 50% (prev 91.07%; Δ 109.2% > 0%) |
| Interest Coverage Ratio: 7.13 > 6 (EBITDA TTM 1.10b / Interest Expense TTM 115.3m) |
Altman Z''
3.22
| A: 0.16 (Total Current Assets 1.80b - Total Current Liabilities 1.03b) / Total Assets 4.64b |
| B: 0.22 (Retained Earnings 1.00b / Total Assets 4.64b) |
| C: 0.17 (EBIT TTM 822.4m / Avg Total Assets 4.76b) |
| D: 0.26 (Book Value of Equity 678.4m / Total Liabilities 2.59b) |
| Altman-Z'' Score: 3.22 = A |
Beneish M
-2.90
| DSRI: 0.53 (Receivables 853.7m/754.5m, Revenue 9.53b/4.44b) |
| GMI: 0.64 (GM 18.07% / 11.65%) |
| AQI: 1.06 (AQ_t 0.58 / AQ_t-1 0.55) |
| SGI: 2.14 (Revenue 9.53b / 4.44b) |
| TATA: -0.02 (NI 495.8m - CFO 601.5m) / TA 4.64b) |
| Beneish M-Score: -2.90 (Cap -4..+1) = A |
What is the price of IMCD shares?
As of May 20, 2026, the stock is trading at EUR 92.30 with a total of 186,764 shares traded.
Over the past week, the price has changed by -4.61%, over one month by -0.58%, over three months by +10.82% and over the past year by -25.38%.
Over the past week, the price has changed by -4.61%, over one month by -0.58%, over three months by +10.82% and over the past year by -25.38%.
Is IMCD a buy, sell or hold?
IMCD has no consensus analysts rating.
What are the forecasts/targets for the IMCD price?
| Analysts Target Price | - | - |
IMCD (IMCD) - Fundamental Data Overview
as of 15 May 2026
Market Cap USD = 6.62b (5.69b EUR * 1.1626 EUR.USD)P/E Trailing = 26.1957
P/E Forward = 14.8368
P/S = 1.1843
P/B = 2.7438
Revenue TTM = 9.53b EUR
EBIT TTM = 822.4m EUR
EBITDA TTM = 1.10b EUR
Long Term Debt = 1.29b EUR (from longTermDebt, last quarter)
Short Term Debt = 325.0m EUR (from shortTermDebt, last quarter)
Debt = 1.70b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.46b EUR (from netDebt column, last quarter)
Enterprise Value = 7.16b EUR (5.69b + Debt 1.70b - CCE 238.6m)
Interest Coverage Ratio = 7.13 (Ebit TTM 822.4m / Interest Expense TTM 115.3m)
EV/FCF = 12.46x (Enterprise Value 7.16b / FCF TTM 574.4m)
FCF Yield = 8.03% (FCF TTM 574.4m / Enterprise Value 7.16b)
FCF Margin = 6.03% (FCF TTM 574.4m / Revenue TTM 9.53b)
Net Margin = 5.20% (Net Income TTM 495.8m / Revenue TTM 9.53b)
Gross Margin = 18.07% ((Revenue TTM 9.53b - Cost of Revenue TTM 7.81b) / Revenue TTM)
Gross Margin QoQ = 8.77% (prev 26.02%)
Tobins Q-Ratio = 1.54 (Enterprise Value 7.16b / Total Assets 4.64b)
Interest Expense / Debt = 2.71% (Interest Expense 46.1m / Debt 1.70b)
Taxrate = 24.91% (29.1m / 117.0m)
NOPAT = 617.5m (EBIT 822.4m * (1 - 24.91%))
Current Ratio = 1.73 (Total Current Assets 1.80b / Total Current Liabilities 1.03b)
Debt / Equity = 0.83 (Debt 1.70b / totalStockholderEquity, last quarter 2.04b)
Debt / EBITDA = 1.33 (Net Debt 1.46b / EBITDA 1.10b)
Debt / FCF = 2.55 (Net Debt 1.46b / FCF TTM 574.4m)
Total Stockholder Equity = 1.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.42% (Net Income 495.8m / Total Assets 4.64b)
RoE = 24.85% (Net Income TTM 495.8m / Total Stockholder Equity 1.99b)
RoCE = 25.03% (EBIT 822.4m / Capital Employed (Equity 1.99b + L.T.Debt 1.29b))
RoIC = 24.97% (NOPAT 617.5m / Invested Capital 2.47b)
WACC = 5.49% (E(5.69b)/V(7.39b) * Re(6.53%) + D(1.70b)/V(7.39b) * Rd(2.71%) * (1-Tc(0.25)))
Discount Rate = 6.53% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 40.45 | Cagr: 1.54%
[DCF] Terminal Value 88.44% ; FCFF base≈497.6m ; Y1≈613.9m ; Y5≈1.05b
[DCF] Fair Price = 489.9 (EV 30.39b - Net Debt 1.46b = Equity 28.92b / Shares 59.0m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -6.09 | EPS CAGR: 3.86% | SUE: N/A | # QB: 0
Revenue Correlation: 78.81 | Revenue CAGR: 15.28% | SUE: -0.06 | # QB: 0
EPS current Year (2026-12-31): EPS=5.74 | Chg30d=+2.29% | Revisions=+33% | GrowthEPS=+10.6% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=6.18 | Chg30d=+1.47% | Revisions=+33% | GrowthEPS=+7.6% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: +33%